Jinhuan Wang's research while affiliated with Tianjin Medical University Cancer Institute and Hospital and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (57)
Purpose:
Prostate cancer (PCa) is often considered as a "cold" tumor with low responsiveness to immunotherapy. Recent evidence suggests the activation of specific immune cells, such as tumor-associated macrophages (TAMs), could potentially influence the efficacy of immunotherapy in PCa. However, the relationship between TAMs and PD-L1, a significa...
Objectives:
This study evaluated the benefits and risks of patients with refractory or relapsed acute lymphocytic leukemia (R/R ALL) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and blinatumomab.
Methods:
PubMed, Web of Science, Embase, and the Cochrane Library were searched for relevant studies.
Results:
The pooled co...
Background
Liver hepatocellular carcinoma(LIHC) is the most common types of cancers.LncRNA has a very important role in the disease progression of LIHC, meanwhile, disufidptosis is a newly discovered mode of tumor cell death that has received high attention.Therefore, we explored the relationship of disufidptosis-related lncRNAs(DTLNS) with clinica...
[This corrects the article DOI: 10.3389/fgene.2022.1092678.].
Background: Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease with a complicated prognosis. Even though various prognostic evaluations have been applied currently, they usually only use the clinical factors that overlook the molecular underlying DLBCL progression. Therefore, more accurate prognostic assessment needs furth...
Background: The diffuse large B-cell lymphoma (DLBCL) is a heterogeneous lymphoma with a dismal outcome, due to approximately 40% patients will be relapsed or refractory to the standard therapy of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Therefore, we need urgently to explore the approach to classify the ri...
Background
We aimed to compare the efficacy of chimeric antigen receptor T (CAR-T) cell therapy with that of autologous stem cell transplantation (auto-HSCT) in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).
Research design and methods
We searched eligible publications up to January 31st, 2022, in PubMed, Cochrane Library, Springer...
Background: Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease that can have profound differences in survival outcomes. A variety of powerful prognostic factors and models have been constructed; however, the development of more accurate prognosis prediction and targeted treatment for DLBCL still faces challenges. An explos...
Diffuse large B cell lymphoma (DLBCL) exhibits a tightly complexity immune landscape. In this study, we intended to identify different immune phenotype and to examine the immune related mRNA signature for clinical characteristic, therapeutic responsiveness as well as risk stratification and survival prediction in DLBCL. We identified two immune inf...
Background:
Nodal Peripheral T cell lymphoma (PTCL) confers a dismal prognosis treated with conventional chemotherapy. Autologous stem cell transplantation (ASCT) seems a reasonable alternative in eligible patients. Nevertheless, a consensus on the role of ASCT as the first-line consolidation therapy for nodal PTCL patients has not been reached so...
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy. Most patients with T-ALL are treated with high-dose multi-agent chemotherapy due to limited targeted therapeutic options. To further investigate its pathogenesis and establish new therapeutic targets, we studied the role of FAPP2, a Golgi protein that is highly e...
Objective: Immune checkpoint inhibitors (ICIs) are effective anti-cancer drugs that can improve survival in cancer patients, but their use may be associated with adverse cardiovascular side effects. Therefore, there is a clinical unmet need to identify non-invasive biomarker to detect subclinical cardiac toxicity after ICI treatment. The aim of thi...
Diffuse large B cell lymphoma (DLBCL) exhibits a tightly complexity immune landscape. In this study, we intended to identify different immune phenotype and to examine the immune related mRNA signature for clinical characteristic, therapeutic responsiveness as well as risk stratification and survival prediction in DLBCL. We separated 738 DLCBL patie...
Chromosomal abnormalities play an important role in classification and prognostication of myelodysplastic syndrome (MDS) patients. However, more than 50% of low-risk MDS patients harbor a normal karyotype. Recently, multiplex ligation-dependent probe amplification (MLPA) has emerged as an effective and robust method for the detection of cytogenetic...
Background: Allogeneic hematopoietic stem cell transplantation(allo-HSCT) consolidation therapy after chimeric antigen receptor(CAR) T cell therapy has emerged as an alternative in patients with B-ALL in the past decade. However, the efficiency remains unclear. In this study, we aimed to systematically analysis the effect of allo-HSCT for Relapse/R...
[This corrects the article DOI: 10.3892/ol.2020.11479.].
Background: Accumulating evidence has indicated the remarkable roles of long non-coding RNAs (lncRNAs) as oncogenes or tumor suppressors in many malignancies. The involvement of lncRNA GATA6-AS1 in cancers remains largely undiscovered. Herein, our research was aimed at elucidating the function and mechanism of GATA6-AS1 in lung adenocarcinoma (LUAD...
Background In myelodysplastic syndromes (MDS), cytogenetic aberrations play an important role for classification and prognostication. However, more than 50% low risk MDS patients harbor a normal karyotype. Recently, multiplex ligation-dependent probe amplification (MLPA) has emerged as an effective and robust method for the detection of cytogenetic...
Background Chromosomal abnormalities play an important role in classification and prognostication of myelodysplastic syndromes (MDS) patients. However, more than 50% low risk MDS patients harbor a normal karyotype. Recently, multiplex ligation-dependent probe amplification (MLPA) has emerged as an effective and robust method for the detection of cy...
Myeloid sarcoma (MS) carries a poor prognosis, and information on epigenetic modifications in MS is currently limited. In the present study, 214 ten-eleven translocation-2 (TET2)-/- mice were successfully constructed. In addition, 436 patients with myelodysplastic syndrome (MDS) and 354 with acute myeloid leukemia (AML) patients were recruited. The...
Background:
Extensive studies revealed that long non-coding RNAs (lncRNAs) could act as a regulator in tumors, including lung adenocarcinoma (LUAD). LncRNA FTX transcript, XIST regulator (FTX) has been reported to regulate the biological behaviors of some cancers. Nevertheless, its functional role and molecular mechanism remain obscure in LUAD. Ou...
Objective:
Patients with non-Hodgkin lymphoma (NHL) occasionally present with multiple primary malignant tumors (MPMTs). This study aimed to determine the clinical characteristics, survival, and risk factors of these patients.
Methods:
The median follow-up of 92 patients was 13.5 months (range 0.3-72). Overall, 21 patients had synchronous MPMTs...
Full scan images of reciprocal co-IPs and Western blots confirming the interaction between Tet2 and Runx1 in HEK293T cells overexpressing FLAG-tagged Tet2 A. Western blotting was performed using indicated antibodies for nuclear lysates from HEK293T cells overexpressing FLAG-vector (Ctrl) or FLAG-Tet2 (Tet2) with anti-Flag IP (related to Figure 5B)....
Genome-wide 5hmC distributions in Tet2−/− and WT macrophages as determined by hMe-Seal
The consensus binding motifs enriched at FLAG ChIP-seq peaks via MEME-ChIP analysis from MEL cells expressing FLAG-Tet2 or FLAG-Ctrl
Information for DhMRs in the genomic regions of Runx1 target genes
Statistical results and gene annotations for DEGs between Tet2−/− and WT macrophages that are also Runx1 target genes (70 out of 206 genes)
List of DEGs in Tet2−/− vs. WT LK cells that are Runx1 target genes (688 out of 3946)
As a dioxygenase, Ten-eleven translocation 2 (TET2) catalyzes subsequent steps of 5-methylcytosine (5mC) oxidation. Tet2 plays a critical role in the self-renewal, proliferation, and differentiation of hematopoietic stem cells, but its impact on mature hematopoietic cells is not well-characterized. Here we show that Tet2 plays an essential role in...
Enrichment of Ep300 and Pu.1 target genes with DhMRs, related to Figure 6 A. GSEA analysis showing decreased gene expression of the Ep300 signature in Tet2−/− macrophages compared with WT macrophages (NES = 1.483, FDR < 1 × 10−4). B. GSEA analysis showing decreased gene expression of the Pu.1 signature in Tet2−/− macrophages compared with WT macrop...
Statistical results and gene annotations for DEGs between Tet2−/− and WT macrophages that are macrophage related genes (111 out of 206 genes)
Statistical results and annotations for genes with altered expression between Tet2−/− and WT macrophages as determined by RNA-seq
Tet2 LC-MS/MS data in MEL cells stably expressing mouse FLAG-Tet2
Correlation analysis of 5hmC and transcriptional changes in Tet2−/− mice
Antibodies used in the current study
The clinical impact of ecotropic viral integration site 1 (EVI1) expression status in myelodysplastic syndromes (MDS) is poorly defined. Here, we investigate the expression of EVI1 and its associated clinical and cytogenetic characteristics in 398 MDS patients. High EVI1 levels (EVI1high) were found more frequently in Higher-risk MDS patients. Othe...
Document S1. Supplemental Experimental Procedures, Figures S1–S5, and Tables S1–S3
Previous studies have suggested that Wilms' tumor gene-1 (WT1) may be related to a decrease in both relapse-free survival (RFS) and overall survival (OS) for patients with myelodysplastic syndrome (MDS). Therefore, we conducted a meta-analysis on the utility of WT1 as a prognostic indicator of MDS. Published reports were searched in the following d...
TET2 is a methylcytosine dioxygenase that regulates cytosine hydroxymethylation. Although there are extensive data implicating a pivotal role of TET2 in hematopoietic stem/progenitor cells (HSPCs), the importance of TET2 in bone marrow mesenchymal stromal cells (BMSCs) remains unknown. In this study, we show that loss of TET2 in BMSCs increases cel...
As a hallmark of epigenetic regulation, DNA methylation plays an important role in regulating gene expression. The TET methylcytosine dioxygenase enzymes (TET1/2/3) catalyze the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), and can further oxidize 5hmC to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Participating...
This paper proposes a new Recurrence Plots method--Symbol Recurrence Plots (SRP), and uses Determinism of SRP (SRP_DET) to quantify the determinism of EEG. The performances, including the effects of weighting coefficients and signal to noise ratios of the SRP are evaluated by using double kinetics Neural Mass Model. The simulation analysis illustra...
The cognitive impairment of type 2 diabetes patients caused by long-term metabolic disorders has been the current focus of attention. In order to find the related electroencephalogram (EEG) characteristics to the mild cognitive impairment (MCI) of diabetes patients, this study analyses the EEG synchronization with the method of multichannel synchro...
EEG characteristics that correlate with the cognitive functions are important in detecting mild cognitive impairment (MCI) in T2DM. To investigate the complexity between aMCI group and age-matched non-aMCI control group in T2DM, six entropies combining empirical mode decomposition (EMD), including Approximate entropy (ApEn), Sample entropy (SaEn),...
Citations
... This phenomenon arises from the fact that both BiTE and CAR operate by means of the direct identification of antigens on malignant cells, thereby triggering the activation of T cells even in the absence of major histocompatibility complex (MHC) antigen presentation. Consequently, these approaches circumvent the various mechanisms employed by tumors to elude the immune system [71]. Two specific BiTE molecules effectively bind cancer cells and T cells and promote cytotoxic T cell responses against tumors [72]. ...
... The tumor microenvironment (TME) may play a role in DLBCL pathogenesis, and the overexpression of MMP9 in microenvironment cells may lead to favorable or unfavorable outcomes [38]. NLE1 is predicted to participate in the Notch signaling pathway and ribosome large subunit assembly, making it a potential target for treating DLBCL patients [39]. PDK1 induces the phosphorylation of PLK1, and then PLK1 directly induces the accumulation of c-Myc protein in a PDK1-dependent manner. ...
... Exosomal lncRNA LINC01268 is also a cancerpromoting factor for pancreatic cancer (29). NME/NM23 family member 8 (NME8) has been identified as a predisposition variant in breast cancer and a prognostic marker in diffuse large B-cell lymphoma (30,31). DMXL2 has also been proposed as a potential therapeutic target for breast cancer and oral mucosal melanoma (32, 33). ...
... Second, there is currently no high-quality evidence proving that CAR T-cell therapy is more effective than ASCT for chemosensitive relapsed DLBCL. 11,12 Third, second-line CAR T-cell therapy is very expensive and not yet funded by some healthcare systems, which at the time of writing this manuscript includes Canada. 13,14 Fourth, we are still learning about the magnitude of short-and long-term toxicity of CAR T-cell therapy, with several series now reporting longterm risks of cytopenias, immune suppression, heart and other organ toxicities, and second malignancies, with approximately 5%-6% 1-year non-relapse mortality rates in the real world setting. ...
... Several studies have examined prognostic factors in patients with DLBCL [2,[4][5][6][7]. However, many of these studies have relied on the conventional Cox proportional hazards model [7,8]. It is important to note that competing mortality events frequently arise during the analysis of survival data. ...
... Jiang et al. developed a prognostic tool based on Differentially Expressed Genes (DEG) from mRNA according to high and low immune infiltration groups obtained via unsupervised hierarchical clustering. Although this contribution lacked an independent validation-set, authors proposed a 16-genes signature showing an AUROC of 0.775 at 3 years of FU for the training-set, outperforming IPI (0.714), and comparably with other relevant works [40][41][42][43][44]. ...
... Apart from the variations in medical care standards over different time periods, methodology of these ASCT studies -which excludes patients with chemotherapy resistant disease -inherently introduces a bias towards selected groups of patients with more chemosensitive disease, making such efficacy comparisons to unselected historical controls speculative at best. A number of previous systematic reviews with meta-analysis looking at role of upfront ASCT for PTCL have been published [9][10][11]. These studies however did not specifically address the role of upfront ASCT for chemosensitive patients, especially those in CR1. ...
... Further, mTOR activation promotes neurotrophic factor-3 expression to induce the regeneration of myelinated axons (56). The abnormal activation or inhibition of the PI3K/Akt/mTOR can cause cancer, immunity, aging, metabolism, and other diseases (57)(58)(59)(60). Considering the aforementioned studies, an in-depth investigation of the mTOR pathway can open avenues in understanding its upstream and downstream mechanisms, as well as its regulation that can be translated to improve neurological conditions. ...
... ICIs are monoclonal antibodies that work by blocking the interaction between tumor cells and immune cells expressing immune checkpoint molecules, thereby promoting the immune system to attack and kill cancer cells [4,5]. However, nonspecific activation of the immune system can lead to a series of immune-related adverse events involving multiple organs [6][7][8][9]. Myocarditis due to ICI is rare, with an incidence of approximately 0.1% [10]. With the rapid increase in the number of related cases, it is suggested that the true incidence of ICI-related myocarditis may be underestimated [11]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/855442779557889-1580964860328_Q64/Mengqi-Gong.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/277047705391104-1443064728184_Q64/Tong-Liu-49.jpg)
... Furthermore, it is well known that iFISH analysis is only able to detect deletion or amplification of sequences larger than 20-50 kb [47], whereas MLPA can recognize sequences of 50-100 nt in length, enabling its application for DNAs even in case of higher template fragmentation [48]. Thus, the need to use alternative methods arises, both in multiple myeloma [49,50] and in other hematological diseases. ...
